Zevra Therapeutics (ZVRA) shares soared 10.4% in the last trading session to close at $8.95. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 13.8% loss over the past four weeks.The surge in share price is likely due to positive investor expectations regarding Zevra’s growth prospects, especially its marketed drug Miplyffa, which is approved to treat a rare genetic disorder called Niemann-Pick disease type C in patients aged two y ...